Free Trial Information
BioCentury | Feb 9, 2021
Management Tracks

Dynavax taps Yu to head vaccine research; plus CFO moves at Lilly, Gemini, Caribou and Lyell

...By BioCentury Staff Dong Yu joined vaccine developer Dynavax Technologies Corp. (NASDAQ:DVAX) as SVP of vaccine research. Yu was...
...CFO. Newton was previously co-head of BofA Securities’ healthcare investment banking practice in the Americas. BC Staff Dynavax Technologies Corp. Eli...
Read More
BioCentury | Jan 21, 2021
Management Tracks

MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar,  and Imara

...By BioCentury Staff Dynavax Technologies Corp. (NASDAQ:DVAX) hired Kelly MacDonald as SVP and CFO, effective March 1. She succeeds...
...He was VP of medical research at Acceleron Pharma Inc. (NASDAQ:XLRN).TARGETSFASN (FAS) – Fatty acid synthase BC Staff Dynavax Technologies Corp. Avrobio...
Read More
BioCentury | Jan 15, 2021
Management Tracks

Frates joins ALS company Amylyx; plus Artios, Valneva, Viravaxx

...record includes vaccine-related roles with Merck & Co. Inc. (NYSE:MRK), Novartis AG (NYSE:NVS; SIX:NOVN) and Dynavax Technologies Corp....
Read More
BioCentury | Dec 12, 2020
Regulation

CHMP’s December opinions include restrictions for Veklury in COVID, support for Daiichi, Seagen breast cancer drugs

...AstraZeneca plc [MERGED] Celltrion Healthcare Co. Ltd. [MERGED] AbbVie Gilead Sciences Inc. Daiichi Sankyo Co. Ltd. Seagen Inc. AstraZeneca plc Innate Pharma S.A. Dynavax Technologies Corp. Bristol...
Read More
BioCentury | Dec 9, 2020
Product Development

Dec. 8 COVID Quick Takes: U.K. Vaccines Taskforce to test combinations, plus advances from Clover, Lilly and India’s Serum Institute

...pivotal trial slated to start next half of the vaccine with CpG 1018, an adjuvant from Dynavax Technologies Corp....
...2 BC Staff AZD1222 (ChAdOx1 nCoV-19) FT516 COVID-19 S-Trimer (SCB-2019) CpG 1018 bamlanivimab, LY-CoV555 (LY3819253) [MERGED] AstraZeneca plc University of Oxford Fate Therapeutics Inc. GlaxoSmithKline plc Dynavax Technologies Corp. Eli...
Read More
BioCentury | Nov 18, 2020
Product Development

COVID-19 Quick Takes: EMA to require more stringent safety monitoring for vaccines; plus J&J, Clover-Thousand Oaks, Medicago-GSK, Inovio and Synairgen

...medRxiv Phase I data for 3.75, 7.5 or 15 µg CoVLP alone or in combination with Dynavax Technologies Corp....
...VLP (CoVLP, MT-2766) CpG 1018 Interferon beta (IFNB) (AZD9412, SNG001, sng-1, SGN-1) Johnson & Johnson Inovio Pharmaceuticals Inc. Medicago Inc. GlaxoSmithKline plc Dynavax Technologies Corp. Synairgen...
Read More
BioCentury | Sep 16, 2020
Product Development

COVID-19 Quick Takes: secondary consequences of COVID-19 in children; plus BioNTech receives funding and expands trial, Regeneron enters RECOVERY, Valneva and Novavax

...two-dose vaccine, adjuvanted with CpG 1018 from Dynavax Technologies Corp....
...slated to enter the clinic in December. Dynavax...
...Drug Administration (FDA) Regeneron Pharmaceuticals Inc. University of Oxford Valneva SE Dynavax Technologies Corp. Novavax...
Read More
BioCentury | Aug 4, 2020
Deals

Dynavax deal gives drug delivery play TriSalus its first therapeutic candidate

...Monday’s deal with Dynavax marks TriSalus’ pivot into therapeutics development. TriSalus Life Sciences gained exclusive, worldwide...
...gained exclusive, worldwide rights to SD-101, a TLR9 agonist, from Dynavax Technologies Corp. (NASDAQ:DVAX). TriSalus will pay Dynavax...
...$5 million up front and $4 million on Dec. 30 to cover R&D expenses, and Dynavax...
Read More
BioCentury | Jul 9, 2020
Product Development

CSL testing coagulation factor blocker in COVID-19 patients; plus vaccine deals and plasma trials

...plc (LSE:GSK; NYSE:GSK) and Dynavax Technologies Corp. (NASDAQ:DVAX) (see “Clover’s Trial” ). Through separate deals, GSK’s and Dynavax’s...
...Delivery” ). BioCentury Staff garadacimab (CSL312) COVID-19 S-Trimer (SCB-2019) CpG 1018 Medicago-COVID-19-unknown COVID-HIG Veklury, remdesivir (GS-5734) CSL Ltd. Coalition for Epidemic Preparedness Innovations (CEPI) GlaxoSmithKline plc Dynavax Technologies Corp. Medicago...
Read More
BioCentury | Jun 19, 2020
Politics, Policy & Law

House lawmakers call for transparency, independent review for COVID-19 vaccine program

...subunit vaccine. The trial will also evaluate separate adjuvants from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Dynavax Technologies Corp....
Read More
Items per page:
1 - 10 of 520
BioCentury | Feb 9, 2021
Management Tracks

Dynavax taps Yu to head vaccine research; plus CFO moves at Lilly, Gemini, Caribou and Lyell

...By BioCentury Staff Dong Yu joined vaccine developer Dynavax Technologies Corp. (NASDAQ:DVAX) as SVP of vaccine research. Yu was...
...CFO. Newton was previously co-head of BofA Securities’ healthcare investment banking practice in the Americas. BC Staff Dynavax Technologies Corp. Eli...
Read More
BioCentury | Jan 21, 2021
Management Tracks

MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar,  and Imara

...By BioCentury Staff Dynavax Technologies Corp. (NASDAQ:DVAX) hired Kelly MacDonald as SVP and CFO, effective March 1. She succeeds...
...He was VP of medical research at Acceleron Pharma Inc. (NASDAQ:XLRN).TARGETSFASN (FAS) – Fatty acid synthase BC Staff Dynavax Technologies Corp. Avrobio...
Read More
BioCentury | Jan 15, 2021
Management Tracks

Frates joins ALS company Amylyx; plus Artios, Valneva, Viravaxx

...record includes vaccine-related roles with Merck & Co. Inc. (NYSE:MRK), Novartis AG (NYSE:NVS; SIX:NOVN) and Dynavax Technologies Corp....
Read More
BioCentury | Dec 12, 2020
Regulation

CHMP’s December opinions include restrictions for Veklury in COVID, support for Daiichi, Seagen breast cancer drugs

...AstraZeneca plc [MERGED] Celltrion Healthcare Co. Ltd. [MERGED] AbbVie Gilead Sciences Inc. Daiichi Sankyo Co. Ltd. Seagen Inc. AstraZeneca plc Innate Pharma S.A. Dynavax Technologies Corp. Bristol...
Read More
BioCentury | Dec 9, 2020
Product Development

Dec. 8 COVID Quick Takes: U.K. Vaccines Taskforce to test combinations, plus advances from Clover, Lilly and India’s Serum Institute

...pivotal trial slated to start next half of the vaccine with CpG 1018, an adjuvant from Dynavax Technologies Corp....
...2 BC Staff AZD1222 (ChAdOx1 nCoV-19) FT516 COVID-19 S-Trimer (SCB-2019) CpG 1018 bamlanivimab, LY-CoV555 (LY3819253) [MERGED] AstraZeneca plc University of Oxford Fate Therapeutics Inc. GlaxoSmithKline plc Dynavax Technologies Corp. Eli...
Read More
BioCentury | Nov 18, 2020
Product Development

COVID-19 Quick Takes: EMA to require more stringent safety monitoring for vaccines; plus J&J, Clover-Thousand Oaks, Medicago-GSK, Inovio and Synairgen

...medRxiv Phase I data for 3.75, 7.5 or 15 µg CoVLP alone or in combination with Dynavax Technologies Corp....
...VLP (CoVLP, MT-2766) CpG 1018 Interferon beta (IFNB) (AZD9412, SNG001, sng-1, SGN-1) Johnson & Johnson Inovio Pharmaceuticals Inc. Medicago Inc. GlaxoSmithKline plc Dynavax Technologies Corp. Synairgen...
Read More
BioCentury | Sep 16, 2020
Product Development

COVID-19 Quick Takes: secondary consequences of COVID-19 in children; plus BioNTech receives funding and expands trial, Regeneron enters RECOVERY, Valneva and Novavax

...two-dose vaccine, adjuvanted with CpG 1018 from Dynavax Technologies Corp....
...slated to enter the clinic in December. Dynavax...
...Drug Administration (FDA) Regeneron Pharmaceuticals Inc. University of Oxford Valneva SE Dynavax Technologies Corp. Novavax...
Read More
BioCentury | Aug 4, 2020
Deals

Dynavax deal gives drug delivery play TriSalus its first therapeutic candidate

...Monday’s deal with Dynavax marks TriSalus’ pivot into therapeutics development. TriSalus Life Sciences gained exclusive, worldwide...
...gained exclusive, worldwide rights to SD-101, a TLR9 agonist, from Dynavax Technologies Corp. (NASDAQ:DVAX). TriSalus will pay Dynavax...
...$5 million up front and $4 million on Dec. 30 to cover R&D expenses, and Dynavax...
Read More
BioCentury | Jul 9, 2020
Product Development

CSL testing coagulation factor blocker in COVID-19 patients; plus vaccine deals and plasma trials

...plc (LSE:GSK; NYSE:GSK) and Dynavax Technologies Corp. (NASDAQ:DVAX) (see “Clover’s Trial” ). Through separate deals, GSK’s and Dynavax’s...
...Delivery” ). BioCentury Staff garadacimab (CSL312) COVID-19 S-Trimer (SCB-2019) CpG 1018 Medicago-COVID-19-unknown COVID-HIG Veklury, remdesivir (GS-5734) CSL Ltd. Coalition for Epidemic Preparedness Innovations (CEPI) GlaxoSmithKline plc Dynavax Technologies Corp. Medicago...
Read More
BioCentury | Jun 19, 2020
Politics, Policy & Law

House lawmakers call for transparency, independent review for COVID-19 vaccine program

...subunit vaccine. The trial will also evaluate separate adjuvants from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Dynavax Technologies Corp....
Read More
Items per page:
1 - 10 of 520